Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: Implications for therapy

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages 582-586

  Maus, Martin K H ^a,b   MacK, Philip C ^c   Astrow, Stephanie H ^b   Stephens, Craig L ^b   Zeger, Gary D ^b,d   Grimminger, Peter P ^a   Hsiang, Jack H ^b   Huang, Eric ^b   Li, Tianhong ^c   Lara, Primo N ^c   Danenberg, Kathleen D ^b   Gandara, David R ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Response Genetics Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biomarkers in NSCLC; ERCC1; Histology; Personalized treatment; RRM1; Sex; TS

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; THYMIDYLATE SYNTHASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CHEMOSENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICRODISSECTION; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 84876407710     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318287c3c5     Document Type: Article

References (37)

1. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-641.
2. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194.
3. Schiller JH, Harrington D, Belani C P, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
4. Scagliotti G V, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
5. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
6. Hanna N, Shepherd FA, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
7. Ozasa H, Oguri T, Uemura T, et al. Signifcance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010;101:161-166.
8. Einhorn LH. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 2008;26:3485-3486.
9. Scagliotti G, Hanna N, Fossella F, et al. The differential effcacy of peme-trexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-263.
10. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as frst-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
11. Ettinger DS, Akerley W, Bepler G, et al.; NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801.
12. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9(Suppl 5):S1-32; quiz S33.
13. Aggarwal C, Somaiah N, Simon RS. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time. J Natl Compr Cancer Netw 2010;8:822-831.
14. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-3546.
15. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
16. Friboulet L, Thomale J, Olaussen K, et al. Functional characterization of ERCC1 isoforms in NSCLC. Cancer Research 2012;72(Suppl 1): abstr 3120.
17. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-2754.
18. Olaussen KA, Dunant A, Fouret P, et al.; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
19. Zheng Z, Chen T, Li X, et al: The DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007:356:800-808
20. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983.
21. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291.
22. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo effcacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-4737.
23. Gong W, Zhang X, Wu J, et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012;75:374-380.
24. Kotsakis A, Yousem S, Gadgeel M, Is Histological Subtype Signifcant in the Management of NSCLC. Open Lung Cancer J 2010;3, 66-72.
25. Redman M W, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res 2012;18:4004-4012.
26. Chansky K, Mack PC, Crowley JJ, Lara PN, Hirsch FR, Franklin WA, Gandara DR. Chemotherapy outcomes by histological subtype of non-small cell lung cancer (NSCLC): analysis of the SWOG database for antimicrotubule-platinum therapy. J Thoracic Oncol 2009;4(Suppl 1).
27. Ferguson MK, Wang J, Hoffman PC, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 2000;69:245-9; discussion 249.
28. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-1802.
29. Foeglé J, Hédelin G, Lebitasy M P, Purohit A, Velten M, Quoix E. Specifc features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997. J Thorac Oncol 2007;2:466-474.
30. Alexiou C, Onyeaka C V, Beggs D, et al. Do women live longer following lung resection for carcinoma? Eur J Cardiothorac Surg 2002;21:319-325.
31. Chang J W, Asamura H, Kawachi R, Watanabe S. Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon? J Thorac Cardiovasc Surg 2009;137:807-812.
32. Hammerman PS, et al. Comprehensive genomic characterization of squa-mous cell lung cancers. Nature 2012;489:519-525.
33. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-1120.
34. Gandara DR, Grimminger P, Mack PC, et al. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 2010;5:1933-1938.
35. Gandara DR, Huang E, Desai S, et al. Thymidylate synthase (TS) gene expression in patients with ALK positive non-small cell lung cancer (NSCLC): Implications for therapy. J Clin Oncol 2012;30(suppl;abstr 7582).
36. Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, Davies AM, Varella-Garcia M, Franklin WA, Doebele RC. Anaplastic Lymphoma Kinase (ALK) gene rearrangements in non-small cell lung cancer are associated with prolonged progression free survival on peme-trexed. J Thoracic Oncol 2011; 6(4):774-780.
37. Shaw AT, Kim D-W, Nakagawa K, et al. Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007). ESMO 37th Annual Meeting 2012;Abstract 2682.